Annual report
6523.TEDINET S100R2R0
Period2022-04-01 → 2023-03-31
Filed2023-06-23
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥356.4bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥340.5bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥306.1bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥272.6bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥186.5bn | 2018-04-01 → 2019-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥20.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥8.2bn | 2021-04-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥179m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥22.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥5.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥20.6bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | −¥3.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥8.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥16.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥5.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥15.5bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | −¥3.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Net income | −¥8.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥561.6bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥591.3bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥569.3bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥529.8bn | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥325.2bn | at 2019-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥422.7bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥455.3bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥138.8bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥136.1bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥107.6bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥138.0bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥135.4bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥107.0bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥70.3bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥65.3bn | at 2019-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥60.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥95.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥45.4bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥50.1bn | at 2019-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥21.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥51.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥47.9bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥36.9bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥33.8bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥17.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥12.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥16.3bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥135.5bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥7.4bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥40.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥7.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥20.4bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥95.6bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥19.9bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥-25.84 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥149.07 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥46.61 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥135.84 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-25.84 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥143.93 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥45.22 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥130.45 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,101.33 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,092.33 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥921.04 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥619.38 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥579.44 | at 2019-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 24.6% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 22.9% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 18.8% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 13.3% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 20.1% | at 2019-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | -2.4% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -7.0% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 19.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 7.8% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 26.0% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 9,403 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 9,374 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 9,753 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 9,615 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 5,368 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥32.9bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥39.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥8.8bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥7.8bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥7.1bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥20.9bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥24.5bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥17.7bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥21.0bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥4.1bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥9.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥606m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥17.7bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥18.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥19.3bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥19.9bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | −¥132m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥10.5bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥137m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥457.3bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥467.3bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥432.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥408.9bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥250.3bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥360.6bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥370.5bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥96.7bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥96.8bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥50.6bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥40.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥50.2bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥22.0bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥50.6bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥154.96 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥166.62 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.17 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-92.71 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.21 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥153.15 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥161.08 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥72 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥38 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥759.31 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥763.79 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥428.12 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥355.31 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥445.36 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 20.8% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 11.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 9.9% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.0% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 20.4% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 27.6% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 125,522,074 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 124,144,242 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 114,831,084 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 111,973,941 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 111,871,099 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 151 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 175 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 181 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 186 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 175 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 35
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 512 pure |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥15.5bn |
| Diabetes Managementreportable segment | employees | at 2023-03-31 | 2639 pure |
| Diabetes Managementreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥111.8bn |
| Diabetes Managementreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥111.8bn |
| Diabetes Managementreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥26.7bn |
| Diagnostics And Life Sciencesreportable segment | employees | at 2023-03-31 | 2388 pure |
| Diagnostics And Life Sciencesreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥108.8bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥108.8bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥1.1bn |
| Healthcare Solutionsreportable segment | employees | at 2023-03-31 | 3864 pure |
| Healthcare Solutionsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥133.6bn |
| Healthcare Solutionsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥133.6bn |
| Healthcare Solutionsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥9.8bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥354.2bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥354.2bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥35.5bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | ¥2.6bn |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2022-03-31 | ¥2.6bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥18.0bn |
| Diabetes Managementreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥109.4bn |
| Diabetes Managementreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥109.4bn |
| Diabetes Managementreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥23.3bn |
| Diagnostics And Life Sciencesreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥92.2bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥92.2bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥14.1bn |
| Healthcare Solutionsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥136.3bn |
| Healthcare Solutionsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥136.3bn |
| Healthcare Solutionsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥17.0bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥337.9bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥337.9bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥26.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 151 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,100
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)梅谷 哲史 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)花岡 克典 | |
| Cpa3 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)西垣内 琢也 | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)病理資金生成単位に配分されたのれんの評価の妥当性 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)連結財務諸表に関する注記事項「３．重要な会計方針 (11）非金融資産の減損」 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row2Member | Original text (Japanese)臨床検査資金生成単位に配分されたのれんの減損に関する判断の妥当性 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row2Member | Original text (Japanese)連結財務諸表に関する注記事項「３．重要な会計方針 (11）非金融資産の減損」 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row3Member | Original text (Japanese)LSIM診断薬資金生成単位に配分されたのれんの減損に関する判断の妥当性 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row3Member | Original text (Japanese)連結財務諸表に関する注記事項「11.のれん及び無形資産」 | |
| Reference2 kam consolidated | FilingDateInstant_Row3Member | Original text (Japanese)連結財務諸表に関する注記事項「３．重要な会計方針(11)非金融資産の減損」 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)梅谷 哲史 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)花岡 克典 | |
| Cpa3 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)西垣内 琢也 | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)Senseonics Holdings, Inc.に対する株式転換権付貸付金及び同社の新株予約権の時価評価の合理性 | |
| Description including reason kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)注記事項（重要な会計上の見積り）1. Senseonics Holdings, Inc.に対する投資有価証券の時価評価」 | |
| Auditors response kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Revenue IFRS (5-year summary) | Prior4YearDuration | 186546000000 | JPY |
| Revenue IFRS (5-year summary) | Prior3YearDuration | 272637000000 | JPY |
| Revenue IFRS (5-year summary) | Prior2YearDuration | 306071000000 | JPY |
| Revenue IFRS (5-year summary) | Prior1YearDuration | 340452000000 | JPY |
| Revenue IFRS (5-year summary) | CurrentYearDuration | 356434000000 | JPY |
| Operating profit loss IFRS (key data) | Prior4YearDuration | 22746000000 | JPY |
| Operating profit loss IFRS (key data) | Prior3YearDuration | 13177000000 | JPY |
| Operating profit loss IFRS (key data) | Prior2YearDuration | 17599000000 | JPY |
| Operating profit loss IFRS (key data) | Prior1YearDuration | 8174000000 | JPY |
| Operating profit loss IFRS (key data) | CurrentYearDuration | 20000000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior4YearDuration | 20650000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior3YearDuration | 5611000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior2YearDuration | 22788000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior1YearDuration | 3002000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | CurrentYearDuration | 179000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior4YearDuration | 15453000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |